Oncocyte (IMDX) Stock Price, News & Analysis

Company Overview

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests that support cancer care. Its products are designed to help physicians assess tumor biology, estimate the risk of disease recurrence or progression, and guide treatment decisions using molecular information from patient samples.

The company’s portfolio has included tissue- and blood-based diagnostic tests for oncology applications, including assays intended to help identify patients who may benefit from particular therapies or require closer monitoring. Oncocyte has also pursued diagnostic solutions related to organ transplantation and other areas where molecular testing may support clinical decision-making.

Oncocyte was founded in 2009 and has operated from California, serving healthcare providers, laboratories, biopharmaceutical companies, and patients through its diagnostic products and collaborations. The company has undergone strategic changes over time as it has refined its product portfolio and commercial focus. Specific current information about its leadership and operations under the NASDAQ: IMDX designation is limited.

Key Stats

• Today's Range: $3.13 to $3.37
• 50-Day Range: $3.17 to $5.12
• 52-Week Range: $2.42 to $8.51
• Volume: 219,318 shs
• Average Volume: 335,031 shs
• Market Capitalization: $103.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.50
• Consensus Rating: Hold

Oncocyte Stock Analysis - MarketRank™

Oncocyte scored higher than 79% of companies evaluated by MarketBeat, and ranked 515th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Oncocyte has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oncocyte has a consensus price target of $10.50, representing about 231.2% upside from its current price of $3.17.

Amount of Analyst Coverage

Oncocyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.04% of the float of Oncocyte has been sold short.

Short Interest Ratio / Days to Cover

Oncocyte has a short interest ratio ("days to cover") of 2.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncocyte has recently decreased by 1.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncocyte does not currently pay a dividend.

Dividend Growth

Oncocyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Oncocyte has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Oncocyte this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncocyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.21% of the stock of Oncocyte is held by insiders.

Percentage Held by Institutions

55.35% of the stock of Oncocyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMDX
• CIK: 1642380
• Web: www.imdxinc.com
• Phone: (949) 409-7600
• Fax: 510-521-3389
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncocyte: $10.50
• High Price Target: $12.00
• Low Price Target: $9.00
• Potential Upside/Downside: +231.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$50.22 million
• Net Margins: -2,955.63%
• Pretax Margin: -2,955.63%
• Return on Equity: N/A
• Return on Assets: -107.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.00
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $4.05 million
• Price / Sales: 25.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.10) per share
• Price / Book: -2.88

Miscellaneous

• Outstanding Shares: 32,720,000
• Free Float: 32,001,000
• Market Cap: $103.72 million
• Optionable: N/A
• Beta: 1.80